TickerFacts.

Volitionrx Ltd (VNRX): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the years ended 2015-12-31, 2016-12-31, 2018-12-31, 2019-12-31 (for example after a spin-off or a discontinued operation), while the year before each was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$19.77M
Year ended 2025-12-31
-$19.58M
Trailing 12 months to 2026-06-30
2011-12-31: -$1.69M2012-12-31: -$2.41M2013-12-31: -$3.08M2014-12-31: -$4.44M2015-12-31: -$8.62M2016-12-31: -$9.28M2017-12-31: -$13.62M2018-12-31: -$14.43M2019-12-31: -$13.25M2020-12-31: -$18.41M2021-12-31: -$21.83M2022-12-31: -$16.85M2023-12-31: -$19.15M2024-12-31: -$26.17M2025-12-31: -$19.77M-$19.77M
2011-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$19.77Mn/m2026-03-31, From 2025-01-01
2024-12-31-$26.17Mn/m2026-03-31, From 2024-01-01
2023-12-31-$19.15Mn/m2025-03-31, From 2023-01-01
2022-12-31-$16.85Mn/m2024-03-25, From 2022-01-01
2021-12-31-$21.83Mn/m2023-03-15, From 2021-01-01
2020-12-31-$18.41Mn/m2022-03-30, From 2020-01-01
2019-12-31-$13.25Mn/c2021-03-22, From 2019-01-01
2018-12-31-$14.43Mn/c2020-02-20, From 2018-01-01
2017-12-31-$13.62Mn/m2019-03-13, From 2017-01-01
2016-12-31-$9.28Mn/c2018-03-01, From 2016-01-01
2015-12-31-$8.62Mn/c2017-03-10, From 2015-01-01
2014-12-31-$4.44Mn/m2016-03-11, From 2014-01-01
2013-12-31-$3.08Mn/m2015-03-18, From 2013-01-01
2012-12-31-$2.41Mn/m2014-03-28, From 2012-01-01
2011-12-31-$1.69Mn/a2013-04-01, From 2011-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Volitionrx Ltd (VNRX)2025-12-31-$19.77Mn/m
Celldex Therapeutics, Inc. (CLDX)2025-12-31-$213.66Mn/m
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31-$25.37Mn/m
Aspira Women's Health Inc. (AWHL)2025-12-31-$7.04Mn/m
Immucell Corp (ICCC)2025-12-31$1.22Mn/m
Alpha Teknova, Inc. (TKNO)2025-12-31-$9.79Mn/m
Intellia Therapeutics, Inc. (NTLA)2025-12-31-$395.87Mn/m
Cardio Diagnostics Holdings, Inc. (CDIO)2025-12-31-$5.91Mn/m
Neogen Corp (NEOG)2026-05-31$31.90Mn/m

Compare VNRX, CLDX, IMDX, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗